Format

Send to

Choose Destination
Methods Mol Biol. 2017;1530:343-353. doi: 10.1007/978-1-4939-6646-2_21.

Artificial Antigen-Presenting Cells for Immunotherapies.

Author information

1
Department of Biomedical Engineering, Yale University, 55 Prospect St., New Haven, CT, 06520, USA.
2
Department of Biomedical Engineering, Yale University, 55 Prospect St., New Haven, CT, 06520, USA. Dongin.Kim@pharmacy.tamhsc.edu.
3
Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M HSC, Reynolds Medical Building Suite 159, Mail Stop 1114, College Station, TX, 77843-1114, USA. Dongin.Kim@pharmacy.tamhsc.edu.

Abstract

Artificial antigen-presenting cells (aAPCs) overcome many of the limitations of biologically based adoptive immunotherapy protocols. While these acellular systems can be designed with a variety of parameters, including material type, diameter, and proliferative signals for T cells, we outline methods to formulate and characterize a comprehensive polymeric microparticle aAPC platform. These aAPCs, which can be reproducibly fabricated in large quantities, efficiently stimulate antigen-specific T cell activation and proliferation by both paracrine cytokine signals and engagement of T cell surface proteins.

KEYWORDS:

Immunotherapy; Microparticle; PLGA; Paracrine delivery; Polymer; aAPC

PMID:
28150213
DOI:
10.1007/978-1-4939-6646-2_21
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center